These dual roles in promoting tumor advancement and immune evasion suggest that MYF5+ MSCs represent an underexplored stromal subset driving immunotherapy resistance, highlighting their potential as a therapeutic target warranting further investigation. Here, MYF5 is linked to neoplasm.